Drug delivery

IntelGenx’s VetaFilm™ Platform to be Evaluated by One of the World’s Fastest Growing Animal Healthcare Companies

Retrieved on: 
Tuesday, June 8, 2021
Pharmaceutical industry, Health sciences, Drug delivery, Medical equipment, Medication, Life sciences, Natural sciences

Pursuant to the Agreement, the Partner will evaluate IntelGenxs proprietary VetaFilm platform in cats.

Key Points: 
  • Pursuant to the Agreement, the Partner will evaluate IntelGenxs proprietary VetaFilm platform in cats.
  • Based on a successful evaluation, IntelGenx and the Partner will enter into negotiations for a commercial agreement in the veterinary field.
  • IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.
  • IntelGenxs superior film technologies, including VersaFilm , DisinteQ, VetaFilm and transdermal VevaDerm, allow for next generation pharmaceutical products that address unmet medical needs.

Connected Drug Delivery Devices Market to Reach US$ 1 Billion by 2027 Globally |CAGR: 25.7%| UnivDatos Market Insights

Retrieved on: 
Wednesday, June 2, 2021
Drug delivery, Medical equipment, Market

The Connected Drug Delivery Devices market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities.

Key Points: 
  • The Connected Drug Delivery Devices market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities.
  • This innovative report makes use of several analyses to get a closer outlook on the Connected Drug Delivery Devices market.
  • The Connected Drug Delivery Devices market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth.
  • Furthermore, this statistical market research repository examines and estimates the Connected Drug Delivery Devices market at the global and regional levels.

Connected Drug Delivery Devices Market to Reach US$ 1 Billion by 2027 Globally |CAGR: 25.7%| UnivDatos Market Insights

Retrieved on: 
Wednesday, June 2, 2021
Drug delivery, Medical equipment, Market

The Connected Drug Delivery Devices market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities.

Key Points: 
  • The Connected Drug Delivery Devices market report has been aggregated by collecting informative data of various dynamics such as market drivers, restraints, and opportunities.
  • This innovative report makes use of several analyses to get a closer outlook on the Connected Drug Delivery Devices market.
  • The Connected Drug Delivery Devices market report offers a detailed analysis of the latest industry developments and trending factors in the market that are influencing the market growth.
  • Furthermore, this statistical market research repository examines and estimates the Connected Drug Delivery Devices market at the global and regional levels.

Phillips-Medisize Unveils Aria Smart Autoinjector Platform to Drive Innovation and Sustainability in Digital Drug Delivery

Retrieved on: 
Wednesday, May 26, 2021
Medical equipment, Life sciences, Autoinjector, Biotechnology, Molex, Drug delivery, Pharmaceutics, Technology

HUDSON, Wis., May 26, 2021 /PRNewswire/ -- Phillips-Medisize, a Molex company and leader in drug delivery, diagnostic and MedTech devices,today unveiled the Aria Smart Autoinjector platform to unlock innovation, differentiation and sustainability in the digital drug-delivery device market.

Key Points: 
  • HUDSON, Wis., May 26, 2021 /PRNewswire/ -- Phillips-Medisize, a Molex company and leader in drug delivery, diagnostic and MedTech devices,today unveiled the Aria Smart Autoinjector platform to unlock innovation, differentiation and sustainability in the digital drug-delivery device market.
  • More than half of pharmaceutical professionals polled expect digital drug delivery to improve patient outcomes for many types of drug treatments.
  • Phillips-Medisize developed the Aria Smart Autoinjector with the compact size and "look and feel" of existing disposable autoinjectors in mind.
  • Aria's reusable drive and disposable cassette help pharmaceutical companies meet growing sustainability mandates while addressing patient preferences for a greener drug delivery device.

MindMed Announces Launch of Collaboration with Nextage Therapeutics' Brain Targeting Liposome System

Retrieved on: 
Monday, May 24, 2021
Psychoactive drugs, Branches of biology, Drugs, NMDA receptor antagonists, Iboga, Opioid antagonists, Drug rehabilitation, Nicotinic antagonists, Noribogaine, Ibogaine, Drug delivery

MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.

Key Points: 
  • MindMed and Nextage will initially collaborate to optimize the delivery of drug products based on noribogaine, and ultimately other ibogaine derivatives, and will share development costs and intellectual property arising from the collaboration.
  • The BTLS technology is an innovative drug delivery system designed to allow the targeted delivery of active pharmaceutical ingredients (APIs) through the Blood Brain Barrier.
  • Nextage CEO, Mr. Abraham Dreazen, said "Our innovative delivery technology has potential to revolutionize brain and CNS treatment.
  • Nextage is pioneering these emerging technologies in Israel and we look forward to working with MindMed and forming a long and successful collaboration."

Global Injectable Drug Delivery Devices Market Report 2021: Market is Expected to Reach $25.79 Billion in 2025 - COVID-19 Impacts, Growth and Changes to 2030 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021
Health, Pharmaceutical, Medical equipment, Drug delivery, Life sciences, Biotechnology

Injectable (parenteral) drug delivery is one of the widely used conventional drug delivery system.

Key Points: 
  • Injectable (parenteral) drug delivery is one of the widely used conventional drug delivery system.
  • Thus, emergence of alternative drug delivery methods limits the growth of injectable drug delivery devices market.\nThe companies in the injectable drug delivery devices are increasingly focusing on the manufacturing of auto injectors.
  • Global Injectable Drug Delivery Devices Market, Segmentation By Type, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion\n6.2.
  • Global Injectable Drug Delivery Devices Market, Segmentation By Application, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion\n'

Odyssey Group International Announces Completion of Novel Device for Nasal Delivery of Concussion Drug Candidate

Retrieved on: 
Wednesday, May 19, 2021
Branches of biology, Medicine, Health sciences, Nose, Dosage forms, Routes of administration, Sensory organs, Nasal administration, Nasal cavity, Drug delivery, Nasal

b'IRVINE, CA, May 19, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of the development of a novel nasal drug delivery device.

Key Points: 
  • b'IRVINE, CA, May 19, 2021 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTCQB: ODYY ) (the "Company" or "Odyssey"), a technology and asset acquisition company focused on developing unique, life-saving medical products, today announced the completion of the development of a novel nasal drug delivery device.
  • The device will be used to deliver the Company\xe2\x80\x99s drug candidate, PRV-002 for concussion treatment and is designed to enhance bio-distribution to the brain.
  • The nasal device will be used in phase 1 clinical trials being scheduled in Australia this summer.
  • \xe2\x80\x9cThis innovation will provide more uniform drug distribution to the nasal cavity while enhancing availability to the brain.

Global Cardiovascular Drug Delivery Markets Report 2021: Diseases, Methods, Cell Therapy, Gene Therapy, Drug-eluting Stents, Key Markets - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 19, 2021
Pharmaceutical, Health, Cardiology, Cardiovascular disease, Drug delivery, Coronary artery disease, Organ systems, Medical specialties, Medicine

b'The "Cardiovascular Drug Delivery - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThe cardiovascular drug delivery markets are estimated for the years 2018 to 2028 on the basis of epidemiology and total markets for cardiovascular therapeutics.\nThe estimates take into consideration the anticipated advances and availability of various technologies, particularly drug delivery devices in the future.

Key Points: 
  • b'The "Cardiovascular Drug Delivery - Technologies, Markets & Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThe cardiovascular drug delivery markets are estimated for the years 2018 to 2028 on the basis of epidemiology and total markets for cardiovascular therapeutics.\nThe estimates take into consideration the anticipated advances and availability of various technologies, particularly drug delivery devices in the future.
  • The role of drug delivery in developing cardiovascular markets is defined and unmet needs in cardiovascular drug delivery technologies are identified.\nDrug delivery to the cardiovascular system is approached at three levels: (1) routes of drug delivery; (2) formulations; and finally (3) applications to various diseases.\nFormulations for drug delivery to the cardiovascular system range from controlled release preparations to delivery of proteins and peptides.
  • Cell and gene therapies, including antisense and RNA interference, are described in full chapters as they are the most innovative methods of delivery of therapeutics.
  • Devices for drug delivery to the cardiovascular system are also described.\nThe role of drug delivery in various cardiovascular disorders such as myocardial ischemia, hypertension, and hypercholesterolemia is discussed.

Global Transdermal Drug Delivery Research Report 2021: Markets, Technologies, and Competitive Landscape 2020-2030 Featuring 100 Companies & 105 Collaborations - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 19, 2021
Health, Pharmaceutical, Health sciences, Routes of administration, Pharmacology, Medicine, Dosage forms, Transdermal patch, Transdermal, Drug delivery

b'The "Transdermal Drug Delivery - Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThe market for transdermal drug delivery is analyzed according to technologies and therapeutic areas from 2020 to 2030.

Key Points: 
  • b'The "Transdermal Drug Delivery - Technologies, Markets, and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThe market for transdermal drug delivery is analyzed according to technologies and therapeutic areas from 2020 to 2030.
  • This market is analyzed according to geographical regions as well.\nThis report deals with transdermal drug delivery - an approach used to deliver drugs through the skin for therapeutic use as an alternative to oral, intravascular, subcutaneous, and transmucosal routes.
  • Various transdermal drug delivery technologies are described including the use of suitable formulations, carriers and penetration enhancers.\nThe most commonly used transdermal system is the skin patch using various types of technologies.
  • Nanoparticles as well as the use of physical agents to facilitate transcutaneous drug delivery is described.

Molex Announces Global Survey Results on Digital Health and Future of Pharma

Retrieved on: 
Tuesday, May 4, 2021
Health sciences, Health, Lisle, Illinois, Molex, Pharma, Adherence, Drug delivery

b'LISLE, Ill., May 4, 2021 /PRNewswire/ -- Molex , a leading global connectivity and electronics solutions provider, and its medical device delivery division, Phillips-Medisize, today announced the results of a global survey of pharmaceutical executives assessing their business strategies, real-life experiences and opinions about the future of digital drug delivery.

Key Points: 
  • b'LISLE, Ill., May 4, 2021 /PRNewswire/ -- Molex , a leading global connectivity and electronics solutions provider, and its medical device delivery division, Phillips-Medisize, today announced the results of a global survey of pharmaceutical executives assessing their business strategies, real-life experiences and opinions about the future of digital drug delivery.
  • The findings validate the growing adoption of digitized drug delivery, with a third of those polled already marketing one or more therapies.
  • "The future of pharma lies in the design and development of patient-focused devices that are easy to use and can collect and connect data seamlessly and securely to personalize treatment while driving increased medication adherence.
  • "\nMolex and Phillips-Medisize commissioned Dimensional Research to conduct The Digital Health and The Future of Pharma Survey in April 2021, polling 215 qualified pharmaceutical professionals representing a range of roles and regions.